Doctors track patients after revolutionary Gene-Editing cure attempt
NCT ID NCT06479616
Summary
This study follows five patients for two years after they received an experimental gene therapy called CS-101 for beta-thalassemia. The goal is to monitor the long-term safety of the treatment and see if patients remain free from needing blood transfusions. Researchers will track any side effects and measure how well the modified blood cells continue to work over time.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Children's Hospital of Fudan University
RECRUITINGShanghai, Shanghai Municipality, 201102, China
Contact Phone: •••-•••-•••• Email: •••••@•••••